310 related articles for article (PubMed ID: 16305990)
21. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
23. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
Breitkreutz I; Anderson KC
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
[TBL] [Abstract][Full Text] [Related]
24. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes.
Castelli R; Cassin R; Cannavò A; Cugno M
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):1-7. PubMed ID: 23153925
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in multiple myeloma: Current status and future potential.
Quach H; Kalff A; Spencer A
Am J Hematol; 2012 Dec; 87(12):1089-95. PubMed ID: 22641420
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide.
Weisel K; Kanz L
Recent Results Cancer Res; 2014; 201():347-57. PubMed ID: 24756803
[TBL] [Abstract][Full Text] [Related]
28. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Pan B; Lentzsch S
Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous adverse reactions to lenalidomide.
Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
[TBL] [Abstract][Full Text] [Related]
30. Thalidomide in myelodysplastic syndromes.
Zorat F; Pozzato G
Biomed Pharmacother; 2002 Feb; 56(1):20-30. PubMed ID: 11905506
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide: an immunomodulatory drug.
Crane E; List A
Future Oncol; 2005 Oct; 1(5):575-83. PubMed ID: 16556034
[TBL] [Abstract][Full Text] [Related]
32. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Schafer PH
Expert Opin Pharmacother; 2012 Jul; 13(10):1541-2. PubMed ID: 22646699
[No Abstract] [Full Text] [Related]
33. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
34. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J; Hsu AK; Johnstone RW
Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
[TBL] [Abstract][Full Text] [Related]
35. Thalidomide and immunomodulatory drugs as cancer therapy.
Raje N; Anderson KC
Curr Opin Oncol; 2002 Nov; 14(6):635-40. PubMed ID: 12409654
[TBL] [Abstract][Full Text] [Related]
36. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Wiernik PH
Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
[TBL] [Abstract][Full Text] [Related]
37. Advances in oral therapy in the treatment of multiple myeloma.
Doss DS
Clin J Oncol Nurs; 2006 Aug; 10(4):514-20. PubMed ID: 16927905
[TBL] [Abstract][Full Text] [Related]
38. Thalidomide analogues as anticancer drugs.
Aragon-Ching JB; Li H; Gardner ER; Figg WD
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):167-74. PubMed ID: 17975653
[TBL] [Abstract][Full Text] [Related]
39. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
List AF
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulatory drugs as a therapy for multiple myeloma.
De Raeve H; Vanderkerken K
Curr Pharm Biotechnol; 2006 Dec; 7(6):415-21. PubMed ID: 17168657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
